[go: up one dir, main page]

PE20020467A1 - Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina - Google Patents

Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina

Info

Publication number
PE20020467A1
PE20020467A1 PE2001000796A PE2001000796A PE20020467A1 PE 20020467 A1 PE20020467 A1 PE 20020467A1 PE 2001000796 A PE2001000796 A PE 2001000796A PE 2001000796 A PE2001000796 A PE 2001000796A PE 20020467 A1 PE20020467 A1 PE 20020467A1
Authority
PE
Peru
Prior art keywords
alkyl
bradycinin
antagonists
methyl
phenyl
Prior art date
Application number
PE2001000796A
Other languages
English (en)
Inventor
Takafumi Ikeda
Tomoki Kato
Yashuhiro Katsu
Makoto Kawai
Mitshuhiro Kawamura
Yuji Shishido
Noriaki Murase
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20020467A1 publication Critical patent/PE20020467A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE A ES HALO; Y ES -(CH2)m-, -C(O)-, -S(O)-; R1 Y R2 SON ALQUILO C1-C4; R3 ES AZACICLO, AZABICICLO, AZATRICICLO-ALQUILO C7-C14, H, ALQUILO C1-C7, PIPERIDINILO, CICLOALQUILO, ENTRE OTROS; R4 ES FENILO SUSTITUIDO EN LA POSICION 2 CON ALQUILO C1-C4, ALQUILO C5-C7, ALCOXI C1-C4, TIOALQUILO C1-C4, AMINO, ALQUILAMINO C1-C4, PIPERAZINILCARBONILO, ENTRE OTROS; R5 ES H, ALQUILO C1-C4; m ES 0-2; n ES 0-5. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. SON COMPUESTOS PREFERIDOS 2-(2-{2-[(2-AMINOETOXI)METIL]FENIL}ETIL)-4-(2,6-DICLOROFENIL)-6-{2-[4-(8-METIL-8-AZABICICLO[3.2.1]OCT-3-IL)-1-PIPERAZINIL]-2-OXOETIL}-1,4-DIHIDRO-3,5-PIRIDINODICARBOXILATO DE DIMETILO, 2-{2-[2-(2-AMINOETOXI)FENIL]ETIL)-4-(2,6-DICLOROFENIL)-6-{2-[4-(8-METIL-8-AZABICICLO[3.2.1]OCT-3-IL)-1-PIPERAZINIL]-2-OXOETIL}-1,4-DIHIDRO-3,5-PIRIDINODICARBOXILATO DE DIMETILO, ENTRE OTROS. LOS COMPUESTOS DE 1,4-DIHIDROPIRIDINA SON ANTAGONISTAS DE BRADICININA Y SON UTILES PARA EL TRATAMIENTO DE INFLAMACION, ASMA, RINITIS ALERGICA
PE2001000796A 2000-08-10 2001-08-08 Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina PE20020467A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22455800P 2000-08-10 2000-08-10

Publications (1)

Publication Number Publication Date
PE20020467A1 true PE20020467A1 (es) 2002-06-14

Family

ID=22841188

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000796A PE20020467A1 (es) 2000-08-10 2001-08-08 Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina

Country Status (21)

Country Link
US (1) US6653313B2 (es)
EP (1) EP1307449B1 (es)
JP (1) JP2004505973A (es)
AP (1) AP2001002238A0 (es)
AR (1) AR034555A1 (es)
AT (1) ATE312099T1 (es)
AU (1) AU2001270947A1 (es)
BR (1) BR0113071A (es)
CA (1) CA2418908C (es)
CR (1) CR6859A (es)
DE (1) DE60115661T2 (es)
ES (1) ES2257422T3 (es)
GT (1) GT200100153A (es)
IL (1) IL153224A0 (es)
IS (1) IS6639A (es)
MX (1) MXPA03001204A (es)
PA (1) PA8525001A1 (es)
PE (1) PE20020467A1 (es)
SV (1) SV2003000588A (es)
TN (1) TNSN01124A1 (es)
WO (1) WO2002012235A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
JP4746318B2 (ja) * 2002-08-30 2011-08-10 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング シクレソニドと抗ヒスタミン剤との組合せ物を含有するアレルギー性鼻炎の治療用医薬組成物
PE20040942A1 (es) * 2003-01-24 2004-12-28 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes
US20060217362A1 (en) * 2004-12-29 2006-09-28 Tung Jay S Novel compounds useful for bradykinin B1 receptor antagonism
ATE540042T1 (de) * 2008-06-09 2012-01-15 Bayer Pharma AG Annelierte 4-(indazolyl)-1,4- dihydropyridinderivate als c-met-mediatoren
WO2010127381A1 (en) * 2009-05-08 2010-11-11 James Cook University Diagnosis, monitoring, prognosis, prevention and treatment of aneurysms
JP5637710B2 (ja) * 2010-03-24 2014-12-10 株式会社トクヤマ ｛２−アミノ−１，４−ジヒドロ−６−メチル−４−（３−ニトロフェニル）−３，５−ピリジンジカルボン酸３−（１−ジフェニルメチルアゼチジン−３−イル）エステル５−イソプロピルエステル｝の製造方法
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
SG10201912411RA (en) 2011-12-28 2020-02-27 Univ California Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2970196B1 (en) 2013-03-15 2020-11-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR20150132146A (ko) 2013-03-15 2015-11-25 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
BR112016008849B8 (pt) 2013-10-25 2022-09-06 Blueprint Medicines Corp Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
FI3102208T4 (fi) 2014-02-07 2024-09-23 Global Blood Therapeutics Inc 2-hydroksi-6-((2-(1-isopropyyli-1h-pyratsol-5-yyli)pyridin-3-yyli)metoksi)bentsaldehydin vapaan emäksen kiteinen polymorfi
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
WO2017096230A1 (en) 2015-12-04 2017-06-08 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
EP4073021A4 (en) * 2019-12-13 2024-02-28 Specialty Operations France PRODUCTION OF BENZENE DERIVATIVES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006083A1 (en) * 1994-08-24 1996-02-29 Pfizer Pharmaceuticals Inc. 2-(piperazinyl-1-carbonylmethyl)-1,4-dihydropyridines as bradykinin antagonists
JP2001510439A (ja) 1996-02-13 2001-07-31 グローバルアート株式会社 ポリエステル環状化合物、その複合体およびその結合体
MX9701245A (es) 1996-02-19 1998-04-30 Pfizer Compuestos de 1,4 dihidropiridina.
TNSN97037A1 (fr) * 1996-02-19 2005-03-15 Pfizer Derives de 1,4 -dihydropyridine, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH11106375A (ja) * 1997-08-18 1999-04-20 Pfizer Pharmaceut Inc ブラジキニンアンタゴニストとしての光学的に活性な１，４−ジヒドロピリジン化合物
ATE257479T1 (de) 1999-12-10 2004-01-15 Pfizer 5-ring heteroarylsubstituierte 1,4- dihydropyridine als bradykinin antagonisten
DE60001535T2 (de) 1999-12-10 2003-10-02 Pfizer Inc., New York Substituierte 1,4-Dihydropyridinverbindungen zur Verwendung als Bradykininantagonisten

Also Published As

Publication number Publication date
US20020161006A1 (en) 2002-10-31
CR6859A (es) 2003-11-25
ES2257422T3 (es) 2006-08-01
SV2003000588A (es) 2003-01-13
WO2002012235A1 (en) 2002-02-14
IS6639A (is) 2002-11-28
IL153224A0 (en) 2003-07-06
ATE312099T1 (de) 2005-12-15
AU2001270947A1 (en) 2002-02-18
AR034555A1 (es) 2004-03-03
GT200100153A (es) 2002-07-03
DE60115661T2 (de) 2006-08-24
TNSN01124A1 (fr) 2005-11-10
EP1307449A1 (en) 2003-05-07
JP2004505973A (ja) 2004-02-26
DE60115661D1 (de) 2006-01-12
PA8525001A1 (es) 2002-08-26
US6653313B2 (en) 2003-11-25
MXPA03001204A (es) 2003-06-30
AP2001002238A0 (en) 2001-09-30
CA2418908C (en) 2006-05-09
CA2418908A1 (en) 2002-02-14
BR0113071A (pt) 2003-07-01
EP1307449B1 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
PE20020467A1 (es) Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina
YU8703A (sh) Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1
PE20040680A1 (es) Inhibidores novedosos de cinasas
PE20011287A1 (es) Derivados de imidazopirimidina y derivados de triazolopirimidina
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR051092A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
HUP0302157A2 (hu) 4-(2-Fenil-tiazol-5-il)-1,4-diazabiciklo[3.2.2]nonán-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
EA200500087A1 (ru) Производные пиперазина
PE20020524A1 (es) 7-oxo-piridopirimidinas como inhibidores de quinasas
PE20050587A1 (es) Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales
PE20050160A1 (es) 3-aminopirrolidinas como inhibidores de la captacion de monoaminas
PE20030719A1 (es) Derivados de 8-[bis(2-halofenil)metil]-3-heteroaril-8-azabiciclo[3.2.1] octan-3-ol como agonistas del receptor de nociceptina orl-1
CO5160261A1 (es) Derivados de bifenilo sustituidos que son antagonistas nk-1, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
ES2099180T3 (es) Derivados del benzopirano y procedimientos para su preparacion.
AR058110A1 (es) Derivados de piperidina
NO20033049D0 (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1
DE60110233D1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
ATE340155T1 (de) Medizinische anwendungen von phenylalkanolen und derivaten davon

Legal Events

Date Code Title Description
FD Application declared void or lapsed